Live Breaking News & Updates on Elizabethi Buchbinder

Stay updated with breaking news from Elizabethi buchbinder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Retrospective Study Shows Nivolumab Associated With OS Benefit After Nivolumab/Ipilimumab irAEs in Advanced Melanoma

Elizabeth I. Buchbinder, MD, discusses findings from a retrospective study evaluating the resumption of nivolumab maintenance therapy in patients with advanced melanoma who discontinued treatment with the combination of nivolumab and ipilimumab due to immune-related adverse effects. ....

United States , Dana Farber Cancer Institute , Elizabethi Buchbinder , Harvard Medical School , Asco Annual Meeting , Immune Related Adverse Effects ,

Major pathologic response to neoadjuvant pemb

<p style="text-align:start">In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.&nbsp;These and other results of the analyses are presented as a proffered paper (Abstract LBA48) at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Monday, October 23, by Sapna P. Patel, MD, chair of the SWOG melanoma committee and associate professor of melanoma medical oncology at the University of Texas MD Anderson Cancer Center.</p>
....

United States , Vernonk Sondak , Michaelc Lowe , Aparna Hegde , Johnm Kirkwood , Kaiser Permanente , Thach Giao Truong , Elizabethi Buchbinder , Larissa Korde , G Paul Wright , Phyllis Gyorkey , Antoni Ribas , Victorg Prieto , Sapnap Patel , Megan Othus , Kari Kendra , Elad Sharon , John Hyngstrom , Sunandana Chandra , Craig Devoe , Data Management Center , Moffitt Cancer Center , University Of Utah Huntsman Cancer Institute , National Institutes Of Health , National Clinical Trials Network , Dana Farber Cancer Institute Harvard Center ,